Disease Landscape and Forecast Insights

Squamous cell carcinoma of the head and neck (SCCHN)—one of the most commonly diagnosed cancers in China—has a dynamic drug development pipeline, including targeted and biomarker-driven…

Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…

Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2031. The treatment of metastatic colorectal cancer is…

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…

Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…

China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…

The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…

China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2021-2031…

The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…

The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…

Squamous cell carcinoma of the head and neck (SCCHN)—one of the most commonly diagnosed cancers in China—has a dynamic drug development pipeline, including targeted and biomarker-driven…